NEW YORK (GenomeWeb News) – Bioinformatics firm Symyx Technologies today said that its board of directors has determined that a bid from Certara to acquire the firm for $5.75 per share in cash does not represent a superior offer to an earlier bid from Accelrys.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.